drugset / Trial / NCT06453057
Autologous Tumor-Infiltrating Lymphocyte (GT307) for Treatment of Patients With Solid Tumours
NaSingle-groupOpen-labelTreatment
Summary
This study is a single arm, open design aimed at evaluating the safety and tolerability of Autologous Tumor-Infiltrating Lymphocyte (GT307) for treatment of patients with solid tumours,while evaluating pharmacokinetic characteristics and efficacy assessment to determine the optimal biological dose (OBD).
Timeline
- Start
- 2024-07-04
- Primary completion
- 2027-06-06
- Completion
- 2027-06-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | GT307 | Cell therapy | — | — |
Indications
No indication recorded.